The Patent Finder
AG

Agensys, Inc.

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

19 patents currently held

11 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Jan 2028. from the record

Of the 11 now held by other companies, 11 name Seagen Inc. as their current owner. Each row says so.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
2
Ending by 2030
Jan 2028
Next term end
3
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents all others Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Feb 8 to 28, 2027 · next Feb 8
  • 1 fee due Oct 12, 2027
    The maintenance fee for Antibody Drug Conjugates (ADC) That Bind to 161P2F10B Proteins (US 9,308,278) comes due Oct 12, 2027. Unpaid by Apr 12, 2028, it lapses early.
  • 1 fee due Nov 12, 2027
    The maintenance fee for Antibody Drug Conjugates (ADC) That Bind to CD37 Proteins (US 10,646,583) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

What they patent

The 2 largest of its 3 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
PatentTitleStatusExpiresConfidence
US 7,622,564Prostate Stem Cell Antigen (PSCA) Variants and Subsequences Thereof
In force
 · High confidence
In forceHigh confidence
US 8,039,597Antibodies and Related Molecules That Bind to 24P4C12 Proteins
In force
 · High confidence
In forceHigh confidence
US 9,308,278Antibody Drug Conjugates (ADC) That Bind to 161P2F10B Proteins
In force
 · High confidence
In forceHigh confidence
US 8,609,092Antibody Drug Conjugates (ADC) That Bind to 161P2F10B Proteins
In force
 · High confidence
In forceHigh confidence
US 9,925,273Antibody Drug Conjugates (ADC) That Bind to CD37 Proteins
In force
 · High confidence
In forceHigh confidence
US 10,646,583Antibody Drug Conjugates (ADC) That Bind to CD37 Proteins
In force
 · High confidence
In forceHigh confidence
US 11,633,500Antibody Drug Conjugates (ADC) That Bind to CD37 Proteins
In force
 · High confidence
In forceHigh confidence
US 11,312,748Derivatives of Dolaproine-Dolaisoleucine Peptides
In force
 · High confidence
In forceHigh confidence
US 12,612,429Derivatives of Dolaproine-Dolaisoleuine Peptides
In force
 · High confidence
In forceHigh confidence
US 9,974,865Antibody Drug Conjugates (ADC) That Bind to FLT3 Proteins
In force
 · High confidence
In forceHigh confidence
10 of 19 patents shown.
Pro members see all 19.
Pro members: see all 19 patents
Also on record, not counted in the 19: 11 patents in force now held by others · 131 patents ended · 12 applications pending · 62 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited